Published in final edited form as:

Obes Surg. 2012 October ; 22(10): 1535–1539. doi:10.1007/s11695-012-0657-5.

CLINICAL EFFICACY OF LAPAROSCOPIC SLEEVE GASTRECTOMY VS LAPAROSCOPIC GASTRIC BYPASS IN OBESE TYPE 2 DIABETIC PATIENTS: A RETROSPECTIVE COMPARISON

PP Cutolo, G Vitolo, V Brancato, and L Angrisani

General and Laparoscopic Surgery Unit, S.Giovanni Bosco Hospital, Naples, Italy

G Nosso* and B Capaldo*

*Department of Clinical and Experimental Medicine, University Federico II, Naples, Italy

Abstract

Background: Roux-en-Y Gastric Bypass (RYGB) and Sleeve 30 Gastrectomy (SG) are performed in patients with obesity and type 2 diabetes mellitus (T2DM). Aim of this study is to evaluate retrospectively the clinical efficacy of RYGB and SG in two groups of obese T2DM patients.

Methods: From the hospital database, we extracted the clinical records of 31 obese T2DM patients, of whom 15 (7F/8M) had undergone laparoscopic SG (LSG) and 16 (7F/9M) laparoscopic RYGB (LRYGB) in the period 2005-2008. The groups were comparable for age (range 33-59y) and BMI (range 38-57kg/m²). LRYGB alimentary limb was 150cm and biliopancreatic limb was 150cm from Treitz ligament. LSG vertical transection was calibrated on a 40F oro-gastric bougie. Data were analyzed at 6,12 and 18-24 months with reference to 40 weight loss and remission of comorbidities.

Results: The reduction in body weight was comparable in the two groups. At 18-24 months the percent BMI reduction was 29±8 and 33±11% in LSG and LRYGB, respectively. Percent excess weight loss was 53±16 and 52±19% in LSG and LRYGB, respectively. Thirteen patients in LSG and 14 patients in LRYGB discontinued their hypoglycemic medications. Five (55%) patients in LSG and 8 (89%) in LRYGB discontinued antihypertensive drugs. Three out of 5 patients in LSG and one out of two patients in LRYGB withdrew lipid lowering agents.

Conclusions: LSG and LRYGB are equally effective in terms of weight loss and remission of obesity-related comorbidities. Controlled long-term comparisons are needed to establish the optimal procedure in relation to patients' characteristics.

Correspondence: dr Pier Paolo Cutolo via E. de Amicis n°16 80040 Terzigno (NA), Italia pierpaolo@cutolo.it; telephone number: +393384010981; fax number: 0817648473.

Presented at the 27th Annual Meeting of the American Society for Metabolic & Bariatric Surgery; 21-26 June 2010 in Las Vegas, Nevada

Keywords

Laparoscopic Gastric Bypass; Sleeve Gastrectomy; Type 2 Diabetes Mellitus; Obesity; Bariatric Surgery

INTRODUCTION

Behavioral and medical approaches to obesity result in a body weight loss of approximately 5 - 10% in the short-term, which tend to wane over time (1). In contrast, bariatric surgery leads to a much greater weight reduction ranging from 50% to 75% of excess body weight (2). More importantly, weight loss is durable as confirmed by long-term follow-up evaluations (3). Therefore, in the recent international guidelines bariatric surgery is presented as the most effective treatment for morbid obesity (4). It is also associated with a high rate of remission of type 2 diabetes mellitus (T2DM) and other obesity-related conditions, namely, hypertension, dyslipidemia and obstructive sleep apnea (5). Adjustable gastric banding (AGB), Roux-en-Y gastric bypass (RYGB) and Sleeve Gastrectomy (SG) are among the most common bariatric interventions (6). RYGB is considered the gold-standard bariatric procedure because of its high success rate balanced against a low rate of adverse events and complications (7). SG, originally developed as a first step for achieving weight loss in superobese patients before performing RYGB or a biliopancreatic diversion with duodenal switch (8), is now viewed as an effective operation on its own (9). In addition, this procedure is no longer considered a purely restrictive intervention since it is associated with changes in some gastrointestinal hormones (10). Indeed, weight loss after SG, at least in short-term, is greater than that obtained with adjustable gastric banding (11). At present, it is difficult to match the different surgical procedures available to different patients' characteristics. Aim of this study is to evaluate the clinical efficacy of laparoscopic RYGB (LRYGB) and laparoscopic SG (LSG) in terms of remission of T2DM and other comorbidities in two comparable groups of obese T2DM patients.

MATERIALS AND METHODS

We prospectively maintained a database of all operated patients and extracted the data of thirty-one obese T2DM patients who underwent bariatric surgery in the period 2005 and 2008 at the Department of Surgery of a tertiary bariatric center. These patients were chosen from a larger group of operated people with T2DM so that the LSG and LRYGB groups were comparable for preoperative anthropometric characteristics. The choice of the surgical procedure was decided by a multidisciplinary team taking into account also, patients' preferences and, above all, the anticipated compliance of patients to lifelong follow-up and nutritional management. Diagnosis of T2DM was made according to the American Diabetes Association (ADA) guidelines. T2DM remission was defined as fasting plasma glucose (FPG) level below 126 mg/dl in the absence of hypoglycemic drugs. Remission of hypertension was defined by discontinuation of antihypertensive treatment; remission of dyslipidemia was defined by discontinuation of lipid-lowering drugs. Improvement of comorbidities was defined by reduction of drugs dosage. In all patients, body weight, BMI, percent excess weight loss (EWL) and FPG were examined

preoperatively and at 6, 12, and 18-24 months after surgery. We also evaluated mortality, peri- and post-operative complications and length of hospital stay with the two types of surgery.

Assays

Plasma glucose and lipid concentrations were measured by enzymatic method. Glycated hemoglobin (HbA1c) was measured by high performance liquid chromatography (HPLC).

Surgical procedures

All procedures were attempted and completed laparoscopically.

LRYGB consisted of a 40 cc gastric pouch. The Roux limb was constructed by transecting the small bowel 100-150 cm distal to the ligament of Treitz (biliopancreatic tract). The circular stapler was introduced transabdominally, to create an ante-colic, ante-gastric end-to-side gastro-jejunostomy. Gastro-jejunostomy was leak tested by injecting 40-60 cc of methylene blue. Jejunio-jejunostomy was performed by a 45-mm linear stapler, 100-150cm distal to the gastro-jejunostomy (alimentary tract; long limb gastric Bypass). For LSG, the gastric greater curvature was freed up to the cardio-oesophageal junction close to stomach and toward the antrum up to 3-5cm from the pylorus. The orogastric tube was calibrated with a 40-Fr boogie. Then the stomach was resected with multiple linear staplers parallel to orogastric tube along the lesser curve starting 3-5cm far from pylorus.

Statistical analysis

Data are reported as mean $\pm$ standard deviation. Paired Student's t- tests were used to compare data before and after surgery within each group. Unpaired Student's t-test was used for comparisons between groups. Statistical significance was set at a p value less than 0.05. All statistical analyses were performed using SPSS version 13.0 (SPSS Inc., Chicago, IL).

RESULTS

The main characteristics of the patients studied are shown in Table 1. Pre-operative body weight was similar in LSG and LRYGB. All patients had a duration of T2DM > 1 year (3 ± 2 years) and most of them (68%) were in poor glycaemic control, as evidenced by HbA1c $> 7\%$. One patient was diet controlled, twenty-six patients were on hypoglycemic agents and four patients were on combined therapy (metformin plus insulin). Nine patients in both 125 groups (60 and 56%) were on antihypertensive therapy; five (33%) patients in LSG and 2 (12%) in LRYGB received lipid lowering agents.

Weight loss

The changes in body weight following LSG and LRYGB are reported in Table 2. The percent reduction in BMI was comparable at 6 months (26 ± 5 and $22 \pm 7\%$), 12 months (29 ± 8 and $36 \pm 19\%$) and 18-24 months (29 ± 8 and $33 \pm 11\%$) in LSG and LRYGB, respectively. Likewise, EWL% was similar in the two groups at all time points of the follow-up.

Improvement/remission of comorbidities

Immediately after interventions, 12 patients in LSG and all patients in LRYGB discontinued their hypoglycemic medications. These results remained essentially unchanged both at 6 than at 18-24 months (Table 3). Only one patient in LRYGB after 20 months 135 showed a value of FPG > 126 mg/dl and a HbA1c >7%. At 18-24 months, FPG was 105 ± 27 and 106 ± 27 mg/dl and HbA1c reduced from baseline value of 7.9 ± 2 to 6.1 ± 0.6 % in LSG and from 8.6 ± 1 to 5.8 ± 0.9 % in LRYGB. Five (55%) patients in LSG and 8 (89%) in LRYGB discontinued antihypertensive drugs. Three out of 5 patients in LSG and one out of two patients in LRYGB discontinued lipid lowering agents. All patients that did not experience complete remission of their comorbidities nonetheless did experience significant improvement (i.e lower doses of medications).

Postoperative outcome

The postoperative length of hospital stay averaged 5 ± 4 days (range 3-25 days). None of the patients required conversion to an open procedure. The 30, 90 day and 24 months mortality was zero. In the LSG group, three patients underwent laparoscopic duodenal switch: one patient was re-operated 15 months after LSG (therefore was excluded from the 18-24 follow-up evaluation); two patients were re-operated after more than 24 months from the first intervention as a sequential treatment of super-obesity. The duodenal switch was performed after the patients had achieved a ~ 25 Kg weight loss and a substantial improvement of comorbidities; all of them underwent duodenal switch for further weight loss. Additional three patients had concomitant procedures during the LSG surgery: one cholecystectomy, one umbelical hernia, one hiatal hernia repair /umbelical hernia. In the LRYGB group, there were three concomitant cholecystectomies and one hiatal hernia repair. Three LRYBG patients devoleped peri-operative complications: one patient had a hematoma of the abdominal wall that was treated conservatively; one patient developed an intestinal volvulus 10 days after surgery that was treated with laparoscopic volvulus derotation; one patient had a prolonged postoperative fever treated conservatively and discharged after 25 days. Two cases of post-operative complications (more than 30 days after surgery) were observed: one case of intestinal occlusion presented 2 years after primary procedure due to internal adhesion and treated successfully with laparoscopic adhesiolysis; one patient has an incisional hernia and is awaiting surgery. In LSG group one patient developed acute renal failure one week after surgery due to severe dehydration; this resolved in a few days.

DISCUSSION

Our study shows that LSG and LRYGB are equally effective in producing a significant weight loss and in improving glucose homeostasis, blood pressure and lipid profile as demonstrated by a similar rate of drugs discontinuation. In contrast, LRYGB showed a higher rate of both peri- and post-operative complications compared to those who had a LSG (31.2% vs 6.6%). Indeed, the only complication in the LSG group occurred in a patient with preexisting diabetic nephropathy and was likely precipitated by limited post-operative fluid intake.

Few studies have compared the clinical efficacy of LRYGB and SG and most of them have been performed in non diabetic subjects (12, 13). In a recent paper, Peterli et al (13) demonstrated that the two procedures improved glucose homeostasis to the same extent in morbidly obese subjects 3-months after surgery by increasing similarly insulin, GLP-1 and PYY levels. Notably, in that study only three patients had T2DM. Our findings extends these observations to diabetic patients and confirm that LSG and LRYGB have a similar clinical efficacy up to 18-24 months follow-up. A systematic review by Buchwald et al reported that bariatric surgery induces an overall remission of T2DM as high as 78% that remained at 62% at 2 years follow-up (2), with malabsorptive procedures more effective than the restrictive ones (95 vs 57 %). With LRYGB a 80% remission rate of T2DM has been reported over 2 years follow-up (2). In our patients, the remission rate of T2DM was 87% in LSG and 94% in LRYGB. The higher rate of T2DM remission obtained in our study can be due to the short duration of the disease (average 3 years); indeed, diabetes duration and preoperative oral hypoglycemic therapy are important determinant of remission. Whether these results will persist longer after surgery remains to be determined.

There is extensive evidence that the remission of T2DM occurs early after bariatric procedures before a significant weight loss is evident (14). This phenomenon has been related to changes in gut hormones consequent to the anatomic modifications of intestinal nutrient transit (15, 16, 17). The more rapid delivery of indigested food to the distal intestine results in a greater release of some entero-hormones such as glucagon-like peptide-1 (GLP-1) (16) which is known to exert multiple beneficial effects on glucose homeostasis. Indeed, plasma GLP-1 levels increase up to 10-fold after bariatric surgery. SG is considered a restrictive procedure and, therefore, the remission of diabetes is expected to be the consequence of weight loss. Actually, in SG two thirds of the stomach are removed, including the gastric fundus where ghrelin-producing cells are located. Since ghrelin is an orexigenic peptide and exerts several diabetogenic effects, it is likely that its suppression contributes to improvement in glucose metabolism.

Although LRYGB is a restrictive-malabsorptive technique whereas LSG is only restrictive, we did not observe significant differences in patients' postoperative eating pattern. The only difference was in their ability of fluid ingestion since the presence of pylorus in LSG strongly limits fluid intake especially in the first 3-6 months.

In the present study we did not compare the two procedures in terms of cost/effectiveness. However, previous publications on this topic indicate that LRYGB surgical costs are quite comparable to those of LSG but reliable long-term outcome data are scarce or lacking (18).

In conclusion, LSG and LRYGB are equally effective in terms of weight loss and remission of obesity-related comorbidities. Controlled long-term comparisons among different bariatric interventions are needed to establish the optimal procedure in relation to patients' characteristics.

References

1. Klein S, Sheard NF, Pi-Sunyer X, et al. Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies: a statement of the American

- Diabetes Association, the North American Association for the Study of Obesity and the American Society for Clinical Nutrition. *Diabetes Care*. 2004; 27:2067–73. [PubMed: 15277443]
2. Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. *Am J Med*. 2009; 122:248–56. [PubMed: 19272486]
 3. Elder KA, Wolfe BM. Bariatric surgery: a review of procedures and outcomes. *Gastroenterology*. 2007; 132:2253–71. [PubMed: 17498516]
 4. Gastrointestinal Surgery for Severe Obesity. NIH Consens Statement. 1991; 9:1–20.
 5. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. *JAMA*. 2004; 292:1724–37. [PubMed: 15479938]
 6. Buchwald H, Oien DM. Metabolic/bariatric surgery Worldwide 2008. *Obes Surg*. 2009; 19:1605–11. [PubMed: 19885707]
 7. Tice JA, Karliner L, Walsh J, et al. Gastric banding or bypass? A systematic review comparing the two most popular bariatric procedures. *Am J Med*. 2008; 121:885–93. [PubMed: 18823860]
 8. Regan JP, Inabnet WB, Gagner M, et al. Early experience with two-stage laparoscopic Roux-en-Y gastric bypass as an alternative in the super-super obese patient. *Obes Surg*. 2003; 13:861–4. [PubMed: 14738671]
 9. Deitel M, Crosby RD, Gagner M. The first international consensus summit for Sleeve Gastrectomy (SG), New York City, October 25–27, 2007. *Obes Surg*. 2008; 18:487–96. [PubMed: 18357494]
 10. Bohdjalian A, Langer FB, Shakeri-Leidenmühler S, et al. Sleeve gastrectomy as sole and definitive bariatric procedure: 5-year results for weight loss and ghrelin. *Obes Surg*. 2010; 20:535–40. [PubMed: 20094819]
 11. Padwal R, Klarenbach S, Wiebe N, et al. Bariatric surgery: a systematic review and network meta-analysis of randomized trials. *Obes Rev*. 2011 Epub ahead of print.
 12. Leyba JL, Navarrete Llopis S. Laparoscopic Roux-en-Y Gastric Bypass Versus Laparoscopic Sleeve Gastrectomy for the Treatment of Morbid Obesity, A prospective Study of 117 Patients *Obes Surg*. 2011; 21:212–16.
 13. Peterli R, Wolnerhanssen B, Peters T, et al. Improvement in glucose metabolism after bariatric surgery: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: a prospective randomized trial. *Ann Surg*. 2009; 250:234–41. [PubMed: 19638921]
 14. Guidone C, Manco M, Valera-Mora E, et al. Mechanisms of recovery from type 2 diabetes after malabsorptive bariatric surgery.; Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. *Diabetes*. 2006; 55:2025–31. [PubMed: 16804072]
 15. Laferrère B, Heshka S, Wang K, et al. Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. *Diabetes Care*. 2007; 30:1709–16. [PubMed: 17416796]
 16. Moo TA, Rubino F. Gastrointestinal surgery as treatment for type 2 diabetes. *Curr Opin Endocrinol Diabetes Obes*. 2008; 15:153–8. [PubMed: 18316951]
 17. Wren AM, Seal LJ, Cohen MA, et al. Ghrelin enhances appetite and increases food intake in humans. *J Clin Endocrinol Metab*. 2001; 86:5992. [PubMed: 11739476]

Table 1

Preoperative characteristics of the patients studied

	LSG n=15	LRYGB n=16	p
Sex (M/F)	7/8	7/9	ns
Age (years)	45 ± 7	45 ± 8	ns
BMI (Kg/m²)	51 ± 8	48 ± 4	ns
EW (%)	129 ± 46	110 ± 24	ns
Blood glucose (mg/dl)	129 ± 38	171 ± 76	ns
HbA1c (%)	7.9 ± 2	8.6 ± 1	ns
Duration of diabetes (years)	3 ± 2	3 ± 2	ns
Hypoglycemic therapy (n)			
diet	0	1	
metformin	13	13	
metformin+insulin	2	2	
Antihypertensive drugs (n)	9	9	
Lipid lowering agents (n)	5	2	

BMI: body mass index; EW: excess weight

Table 2

Changes in BMI, percent BMI and percent EWL after LSG and LRYGB

	BMI (Kg/m ²)			Decrease in BMI (%)			EWL (%)		
	LSG	LRYGB	p*	LSG	LRYGB	p*	LSG	LRYGB	p*
6 months	39 ± 7	37 ± 5	ns	26 ± 5	22 ± 7	ns	47 ± 12	44 ± 13	ns
12 months	36 ± 6	32 ± 4	ns	29 ± 8	36 ± 19	ns	54 ± 15	60 ± 17	ns
18-24 months	36 ± 7 ^o	32 ± 5	ns	29 ± 8	33 ± 11	ns	53 ± 16	52 ± 19	ns

BMI: body mass index; EWL: excess weight loss

* comparison between groups

^o
n=14

Table 3

Number of patients who discontinued the pharmacological treatment

	6 m		12 m		18-24 m	
	LSG n (%)	LYGB n (%)	LSG n (%)	LYGB n (%)	LSG n (%)	LYGB n (%)
Hypoglycemic drugs	12 (80)	15 (100)	13 (87)	14 (93)	13 (87)	14 (93)
Anti-hypertensive drugs	4 (44)	7 (78)	5 (56)	7 (78)	5 (56)	8 (89)
Hypolipidemic drugs	3 (60)	1 (50)	3 (60)	1 (50)	3 (60)	1 (50)